Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash from Financing Activities: 2014-2025

Historic Cash from Financing Activities for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $2,000.

  • Coherus Oncology's Cash from Financing Activities rose 101.20% to $2,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$281.6 million, marking a year-over-year decrease of 50.69%. This contributed to the annual value of -$187.0 million for FY2024, which is 368.64% down from last year.
  • Per Coherus Oncology's latest filing, its Cash from Financing Activities stood at $2,000 for Q3 2025, which was up 100.00% from -$281.5 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Cash from Financing Activities ranged from a high of $54.3 million in Q2 2023 and a low of -$281.5 million during Q2 2025.
  • For the 3-year period, Coherus Oncology's Cash from Financing Activities averaged around -$36.3 million, with its median value being $231,000 (2024).
  • In the last 5 years, Coherus Oncology's Cash from Financing Activities skyrocketed by 7,434.67% in 2023 and then tumbled by 445.93% in 2024.
  • Quarterly analysis of 5 years shows Coherus Oncology's Cash from Financing Activities stood at $1.5 million in 2021, then spiked by 343.38% to $6.6 million in 2022, then crashed by 94.45% to $366,000 in 2023, then tumbled by 36.89% to $231,000 in 2024, then surged by 101.20% to $2,000 in 2025.
  • Its Cash from Financing Activities stands at $2,000 for Q3 2025, versus -$281.5 million for Q2 2025 and -$264,000 for Q1 2025.